07:00 , Sep 1, 2016 |  BC Innovations  |  Tools & Techniques

Democratizing antibodies

With the goal of expanding access to antibody-based drugs worldwide, the Bill & Melinda Gates Foundation is turning to industry to innovate its methods of manufacturing the proteins. In the last two months, the organization...
00:36 , May 7, 2016 |  BC Extra  |  Clinical News

HIV-1 antibody boosts immunity, may shrink viral reservoir

Clinical and mouse studies published online Thursday in Science showed broadly neutralizing anti-HIV-1 antibody 3BNC117 neutralized free virions, boosted host immunity against the virus, and may shrink the pool of latently infected cells known...
07:00 , Apr 20, 2015 |  BC Week In Review  |  Clinical News

3BNC117: Phase I data

An open-label, dose-escalation, U.S. and German Phase I trial in 17 patients with HIV-1 infection and 12 uninfected subjects showed that single doses of 1, 3, 10 and 30 mg/kg IV 3BNC117 were generally well...
08:00 , Dec 5, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HIV/AIDS HIV gp120 Nonhuman primate studies suggest combining the anti-HIV gp120 mAbs 3BNC117 and 10-1074 could...